title: [Analysis on morbidity and mortality of viral hepatitis in China, 2004-2013].
abstract: OBJECTIVE
  To understand the incidence and death patterns of viral hepatitis in China and provide evidence for the prevention and control of viral hepatitis.
  
  
  METHODS
  The analysis was conducted on the incidence and death data of viral hepatitis published by National Health and Family Planning Commission during 2004-2013.
  
  
  RESULTS
  The incidences of viral hepatitis in Guizhou,Yunnan, Tibet, Gansu, Qinghai,Ningxia and Xinjiang provinces (autonomous region) were high. The major forms were hepatitis B (80.63/100 000) and hepatitis C (9.68/100 000), accounting for 80.90% and 9.25% of the total reported viral hepatitis cases respectively. The incidences of hepatitis A and unidentified hepatitis decreased and the incidence of hepatitis B, C and E increased during this period. During the 10 years, 10 008 deaths caused by viral hepatitis were reported (1 001 deaths per year). The reported deaths caused by hepatitis A, hepatitis E and unidentified hepatitis decreased during this period. The reported deaths caused by hepatitis B were in a downward trend, but the constituent in total cases remained high. The reported deaths caused by hepatitis C were in an upward trend.
  
  
  CONCLUSIONS
  During 2004-2013, the overall incidence of viral hepatitis showed no downward trend in China. The incidence of hepatitis B remained high, and the incidence of hepatitis C showed an obvious upward trend. The overall death rate and case fatality rate of viral hepatitis showed a downward trend, but hepatitis B remained the main cause of viral hepatitis related death, and the death caused by hepatitis C was in increase. Hepatitis B and hepatitis C are the major targets in the prevention and treatment of viral hepatitis in China, and the 7 western provinces (autonomous region) with high incidences are the key regions of the prevention and control.
authors.affiliation: Medical School of Chinese People's Liberation Army, Beijing 100853, China; Center of Therapeutic Research for Hepatocellular Carcinoma.
authors.forename: Minna
authors.initials: M
authors.lastname: Zhang
authors.affiliation: Department of Nosocomial Infection Control.
authors.forename: Yue
authors.initials: Y
authors.lastname: Yuan
authors.affiliation: Medical School of Chinese People's Liberation Army, Beijing 100853, China; Experimental Technology Support and Research Center, 302 Hospital of Chinese People's Liberation Army. Email: maopy302@163.com.
authors.forename: Panyong
authors.initials: P
authors.lastname: Mao
authors.affiliation: Department of Nosocomial Infection Control. Email: yingjiezhuang@sina.com.
authors.forename: Yingjie
authors.initials: Y
authors.lastname: Zhuang
mesh_terms: D002681:China / Q000453:epidemiology; D002690:Chlamydia Infections; D016174:Hepacivirus; D006506:Hepatitis A / Q000401:mortality*; D006509:Hepatitis B / Q000401:mortality*; D006526:Hepatitis C / Q000401:mortality*; D006801:Humans; D015994:Incidence; D008288:Malaria; D009017:Morbidity; D018609:Tibet / Q000453:epidemiology